Pathophysiology of CF and CFTR directed therapies

F. Ratjen (Toronto, Canada)

Source: ERS course 2015

Number: 1

Disease area: Paediatric lung diseases

Rating:

You must login to grade this presentation.

Share or cite this content

Citations should be made in the following way:
F. Ratjen (Toronto, Canada). Pathophysiology of CF and CFTR directed therapies. ERS course 2015

You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.

Member's Comments

No comment yet.

You must Login to comment this presentation.

Related content which might interest you:

Targeting CFTR as a therapy for cystic fibrosis Source: Lung Science Conference 2010 - Biology of gene-environment interactions in the lung Year: 2010
Personalised CFTR pharmacotherapeutic response testing and therapy of cystic fibrosis Source: Eur Respir J, 51 (6) 1702457; 10.1183/13993003.02457-2017 Year: 2018
CFTR targeted therapies: recent advances in cystic fibrosis and possibilities in other diseases of the airways Source: Eur Respir Rev, 29 (156) 190068; 10.1183/16000617.0068-2019 Year: 2020
Novel therapeutics for CF Source: International Congress 2019 – Future of cystic fibrosis care: insights from the Lancet Commission Year: 2019
ENaC inhibition in cystic fibrosis: potential role in the new era of CFTR modulator therapies Source: Eur Respir J, 56 (6) 2000946; 10.1183/13993003.00946-2020 Year: 2020
Clinical development of triple-combination CFTR modulators for cystic fibrosis patients with one or two F508del alleles Source: ERJ Open Res, 5 (2) 00082-2019; 10.1183/23120541.00082-2019 Year: 2019
Combination of ENaC and CFTR mutations may predispose to cystic fibrosis-like disease Source: Eur Respir J 2009; 34: 772 Year: 2009
Progress in precision medicine in cystic fibrosis: a focus on CFTR modulator therapy Source: Breathe, 17 (4) 210112; 10.1183/20734735.0112-2021 Year: 2021
Novel therapeutics for cystic fibrosis Source: ERS Webinar 2020: Novel therapeutics for cystic fibrosis Year: 2020
Correction of CFTR function in intestinal organoids to guide treatment of cystic fibrosis Source: Eur Respir J, 57 (1) 1902426; 10.1183/13993003.02426-2019 Year: 2021
Measuring CFTR function in respiratory epithelial cell cultures: step to individualize treatments in cystic fibrosis? Source: Virtual Congress 2021 – Monitoring of lung disease and CFTR function in children with cystic fibrosis Year: 2021
Potential therapeutic use of 12-Lipoxygenase inhibitors in the treatment of mucus overproduction in cystic fibrosis Source: Research Seminar 2009 - Molecular and Cellular aspects of Chronic Lung Disease Year: 2009
Role of CF ion transport defect in airway inflammation and implication for antiinflammatory therapies Source: Research Seminar 2012 - Pulmonary inflammation in paediatric respiratory disease Year: 2012
Targeting a genetic defect: cystic fibrosis transmembrane conductance regulator modulators in cystic fibrosis Source: Eur Respir Rev 2013; 22: 58-65 Year: 2013
Targeting airway inflammation in asthma: current and future therapies Source: Annual Congress 2009 - MP7 - Targeting airway inflammation in asthma: current and future therapies Year: 2009
Targeting airway inflammation in asthma: current and future therapies Source: Annual Congress 2009 - PG13 Asthma: pathology and treatment Year: 2009
Genotype specific therapies for cystic fibrosis Source: Annual Congress 2004 - New approaches to cystic fibrosis: from cells and molecules to novel therapies Year: 2004
Ivacaftor treatment in patients with cystic fibrosis and the G551D-CFTR mutation Source: Eur Respir Rev 2013; 22: 66-71 Year: 2013
CF: pathogenesis treatment strategies Source: International Congress 2018 – Russian Speaking Programme 2018: Part I Year: 2018